Austin、TXにおけるがん（全種類）の臨床試験
Austinとその周辺地域（約30マイル以内）の拠点で、がん（全種類）に関する20件の研究が参加者を募集しています。研究を開いて、参加資格と連絡方法を確認してください。
公式研究テキスト（英語）
ここで研究参加者を募集していますか？ このページの上部に表示できます — 30日間 $99 →
A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies
被験者募集中第2相
- Texas Oncology-Austin North /ID# 279958, Austin
Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer (EV-309)
被験者募集中第3相
- Texas Oncology, Austin
A Study of NEOK001, a B7-H3 and ROR1 Targeting Bispecific ADC in Participants With Select Solid Tumors
被験者募集中第1相
- NEXT Oncology, Austin
Prospective Study to Assess a Diagnostic Aid for Cancer
被験者募集中観察研究
- Premier Family Physicians, Austin
RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses
被験者募集中第2相
- Dell Medical School, University of Texas at Austin, Austin
A Study to Evaluate the Safety and Efficacy of MK-3120 in Participants With Advanced Solid Tumors (MK-3120-002)
被験者募集中第1/2相
- NEXT Oncology ( Site 1010), Austin
A Phase 1/1b Study of IAM1363 in HER2 Cancers
被験者募集中第1相
- NEXT Oncology - Austin, Austin
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
被験者募集中第3相
- USO - Texas Oncology, Austin
Project: Every Child for Younger Patients With Cancer
被験者募集中観察研究
- Dell Children's Medical Center of Central Texas, Austin
A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors
被験者募集中第1相
- Texas Oncology - Central South, Austin
A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma
被験者募集中第1相
- Texas Oncology - Central/South Texas /ID# 268563, Austin
A Study to Assess Adverse Events and Change in Disease Activity in Adult Participants Receiving Intravenously Infused Telisotuzumab Adizutecan Alone or With Standard of Care in Participants With Post Adjuvant Circulating Tumor DNA Positive Colorectal Cancer and No Radiographic Evidence of Disease
被験者募集中第2相
- Texas Oncology - Central/South Texas /ID# 275154, Austin
A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
被験者募集中第2/3相
- Texas Oncology - South Austin /ID# 276033, Austin
Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer
被験者募集中第2相
- Texas Oncology - Austin Central, Austin
A Study of GSK5764227 in Participants With Advanced Solid Tumors (EMBOLD)
被験者募集中第1相
- GSK Investigational Site, Austin
Phase I Study of SYS6043 in Patients With Advanced/Metastatic Solid Tumors
被験者募集中第1相
- NEXT Oncology Austin, Austin
Safety, PK, and Preliminary Efficacy of MBRC-101 in Advanced Refractory Solid Tumors
被験者募集中第1/2相
- NEXT Oncology, Austin
Beat Childhood Cancer Specimen Banking and Data Registry
被験者募集中観察研究健康なボランティア歓迎
- Dell Children's Blood and Cancer Center, Austin
A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents
被験者募集中第1/2相
- NEXT Austin, Austin
A Study in Patients With Advanced Cancers
被験者募集中第1/2相
- NEXT Oncology Austin, Austin
他の都市におけるがん（全種類）の試験
- Houston, TX121件の研究
- New York City, NY110件の研究
- Boston, MA86件の研究
- Los Angeles, CA73件の研究
- Nashville, TN65件の研究
- Philadelphia, PA59件の研究
- Durham, NC58件の研究
- Washington, DC58件の研究
- Chicago, IL51件の研究
- Seattle, WA49件の研究
- Atlanta, GA49件の研究
- Arlington, VA48件の研究
Austinにおける他の研究
- 非小細胞肺癌30件の研究
- 肥満症20件の研究
- 転移性癌19件の研究
- 大腸癌19件の研究
- 心不全18件の研究
- 乳がん18件の研究
- 過体重18件の研究
- 卵巣がん17件の研究
- 子宮内膜がん15件の研究
- 前立腺がん15件の研究
- うつ病14件の研究
- トリプルネガティブ乳がん13件の研究
ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。